ERK1/2 MAP kinases: Structure, function, and regulation

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

MAP kinase signalling pathways in cancer

Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995

Protein Tyrosine Phosphatases in the Human Genome

Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886

The resurgence of covalent drugs

Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817

RAS oncogenes: weaving a tumorigenic web

Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789

Mitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers

Schaeffer, H. J., & Weber, M. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2435 · Cited by 1,600 · cited 1×

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997

ERK/MAPK signalling pathway and tumorigenesis (Review)

Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886

Tumor adaptation and resistance to RAF inhibitors

Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585

RAF-MEK-ERK pathway in cancer evolution and treatment

Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553

Properties of FDA-approved small molecule protein kinase inhibitors

Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413

Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes

Oláh, A., Tóth, B. I., Borbíró, I., Sugawara, K., Szöllõsi, A. G., Czifra, G., Pál, B., Ambrus, L., Kloepper, J., Camera, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci64628 · Cited by 268

The 16p11.2 Deletion Mouse Model of Autism Exhibits Altered Cortical Progenitor Proliferation and Brain Cytoarchitecture Linked to the ERK MAPK Pathway

Pucilowska, J., Vithayathil, J., Tavares, E. J., Kelly, C., Karlo, J. C., & Landreth, G. E. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4864-13.2015 · Cited by 207

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers

Ségaliny, A. I., Tellez-Gabriel, M., Heymann, M.-F., & Heymann, D. (2015) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.01.001 · Cited by 164

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer

Johnson, G. L., Stuhlmiller, T. J., Angus, S. P., Zawistowski, J. S., & Graves, L. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1081 · Cited by 129

Complex molecular regulation of tyrosine hydroxylase

Tekin, I., Roskoski, R., Carkaci-Salli, N., & Vrana, K. E. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1238-7 · Cited by 128

Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors

Lv, X., Lu, X., Cao, J., Luo, Q., Ding, Y., Peng, F., Pataer, A., Lu, D., Han, D., Malmberg, E., et al. (2023) · Science · doi:10.1126/science.abn4180 · Cited by 123

Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters

Bermingham, D. P., & Blakely, R. D. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012260 · Cited by 97

A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes

Wu, H.-T., Ou, H.-Y., Hung, H.-C., Su, Y.-C., Lu, F.-H., Wu, J.-S., Yang, Y.-C., Wu, C.-L., & Chang, C.-J. (2016) · Diabetologia · doi:10.1007/s00125-016-3991-7 · Cited by 96

Phosphoregulation of the WAVE regulatory complex and signal integration

Mendoza, M. C. (2013) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2013.01.007 · Cited by 94

Protein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway

García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72

The Candida albicans toxin candidalysin mediates distinct epithelial inflammatory responses through p38 and EGFR-ERK pathways

Nikou, S.-A., Zhou, C., Griffiths, J. S., Kotowicz, N. K., Coleman, B. M., Green, M. J., Moyes, D. L., Gaffen, S. L., Naglik, J. R., & Parker, P. J. (2022) · Science Signaling · doi:10.1126/scisignal.abj6915 · Cited by 65

Relaxation oscillations and hierarchy of feedbacks in MAPK signaling

Kochańczyk, M., Kocieniewski, P., Kozłowska, E., Jaruszewicz-Błońska, J., Sparta, B., Pargett, M., Albeck, J. G., Hlavacek, W. S., & Lipniacki, T. (2017) · Scientific Reports · doi:10.1038/srep38244 · Cited by 59

Restoring Effects of Natural Anti-Oxidant Quercetin on Cellular Senescent Human Dermal Fibroblasts

Sohn, E.-J., Kim, J. M., Kang, S.-H., Kwon, J., An, H. J., Sung, J.-S., Cho, K. A., Jang, I.-S., & Choi, J.-S. (2018) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x18500453 · Cited by 48

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Holkova, B., Zingone, A., Kmieciak, M., Bose, P., Badros, A. Z., Voorhees, P. M., Baz, R., Korde, N., Lin, H.-Y., Chen, J.-Q., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1076 · Cited by 48

ERK1/2 phosphorylates HIF-2α and regulates its activity by controlling its CRM1-dependent nuclear shuttling

Gkotinakou, I.-M., Befani, C., Simos, G., & Liakos, P. (2019) · Journal of Cell Science · doi:10.1242/jcs.225698 · Cited by 43

Picroside II Inhibits the MEK-ERK1/2-COX2 Signal Pathway to Prevent Cerebral Ischemic Injury in Rats

Wang, T., Zhai, L., Zhang, H., Zhao, L., & Guo, Y. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0623-5 · Cited by 28

ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice

Shen, M., Lv, D., Liu, X., & Wang, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02290-5 · Cited by 22

Expression and activation of mitogen-activated protein kinases in the optic nerve head in a rat model of ocular hypertension

Mammone, T., Chidlow, G., Casson, R. J., & Wood, J. P. M. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.01.002 · Cited by 18

Live imaging approach of dynamic multicellular responses in ERK signaling during vertebrate tissue development

Hirashima, T. (2022) · Biochemical Journal · doi:10.1042/bcj20210557 · Cited by 12

RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation

Crowe, M. S., Zavorotinskaya, T., Voliva, C. F., Shirley, M. D., Wang, Y., Ruddy, D. A., Rakiec, D. P., Engelman, J. A., Stuart, D. D., & Freeman, A. K. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-1022 · Cited by 6

Coronaviruses spike glycoprotein endodomains: The sequence and structure‐based comprehensive study

Kumar, P., Bhardwaj, A., Mukherjee, B., Joshi, R., & Giri, R. (2023) · Protein Science · doi:10.1002/pro.4804 · Cited by 2

Data from RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation

(2023) · doi:10.1158/1541-7786.c.6544943